Furthermore, there was no significant difference in terms of pathologic features (Ki-67 labeling index, mitosis, presence of Crooke cells), adenoma size, weight change, total pasireotide treatment time, initial and last pasireotide treatment dose, the time between pituitary surgery and initiation of pasireotide treatment, and median systolic/diastolic blood pressures between the controlled and uncontrolled patients. This evidence concerns the gene MKI67 and adenoma.